Skip to main content

Otezla FDA Approval History

Last updated by Judith Stewart, BPharm on July 20, 2019.

FDA Approved: Yes (First approved March 21, 2014)
Brand name: Otezla
Generic name: apremilast
Dosage form: Tablets
Company: Celgene Corporation
Treatment for: Psoriatic Arthritis, Plaque Psoriasis, Behcet's Disease

Otezla (apremilast) is a phosphodiesterase 4 (PDE4) inhibitor indicated for the treatment of psoriatic arthritis, plaque psoriasis, and oral ulcers associated with Behçet’s Disease.

Development Timeline for Otezla

DateArticle
Jul 19, 2019Approval  FDA Approves Otezla (apremilast) for the Treatment of Oral Ulcers Associated with Behçet’s Disease
Sep 23, 2014Approval  FDA Approves Otezla (apremilast) for Moderate to Severe Plaque Psoriasis
Mar 21, 2014Approval  FDA Approves Otezla (apremilast) to Treat Psoriatic Arthritis

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.